Search

Your search keyword '"Wimberger, Pauline"' showing total 85 results

Search Constraints

Start Over You searched for: Author "Wimberger, Pauline" Remove constraint Author: "Wimberger, Pauline" Database OpenAIRE Remove constraint Database: OpenAIRE
85 results on '"Wimberger, Pauline"'

Search Results

1. Additional file 2 of The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy

2. Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer : results of a multicentre, open label phase I/II study (TOPAZ)

3. Psychische Belastung und deren Einflussfaktoren bei Überlebenden von malignen ovariellen Keimzell- oder Keimstrangstromatumoren : Eine Analyse der AGO-CORSETT-Datenbank

4. Additional file 1 of The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy

5. Long-term effects of antenatal synthetic glucocorticoids on epigenetic regulation of stress-associated genes

7. Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A₁₆₅b, an Antiangiogenic VEGF-A Splice Variant

8. Diagnosis, therapy and follow-up of cervical cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF registry no. 032/033OL, May 2021) – part 2 with recommendations on psycho-oncology, rehabilitation, follow-up, recurrence, palliative therapy and healthcare facilities

9. SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study

10. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany

11. Diphenhydramine increases the therapeutic window for platinum drugs by simultaneously sensitizing tumor cells and protecting normal cells

12. Clinical relevance of circulating MACC1 and S100A4 transcripts for ovarian cancer

13. Diagnosis of first relapse and its impact on quality of life in patients with advanced ovarian cancer (AGO-OVAR 19/II)

14. CRBP-TS - evaluation of a home-based training and health care program for colorectal, breast, and prostate cancer using telemonitoring and self-management: study protocol for a randomized controlled trial

15. Efficacy of the tyrosine kinase inhibitor lapatinib in the treatment of patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells : results from the randomized phase III DETECT III trial

16. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program

17. Supplement for No Long-Term Effects of Antenatal Synthetic Glucocorticoid Exposure on Epigenetic Regulation of Stress-Related Genes

18. Pelvine Lymphonodektomie beim Vulvakarzinom - Wohl oder Übel?

19. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab

20. Corrigendum to ‘clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome’ (EBioMedicine (2019) 43 (253–260), (S2352396419302142), (10.1016/j.ebiom.2019.03.069))

21. Corrigendum to ‘clinical and genetic landscape of treatment naive cervical cancer:Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome’ (EBioMedicine (2019) 43 (253–260), (S2352396419302142), (10.1016/j.ebiom.2019.03.069))

22. Additional file 6 of Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer

24. Additional file 2 of Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer

25. Additional file 1 of Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer

27. Additional file 5 of Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer

28. Additional file 3 of Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer

29. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

30. The effect of surgical techniques on sexuality and global quality of life (Qol) in women with ovarian germ cell (OGCT) and sex cord stromal tumours (SCST) : An analysis of the AGO-CORSETT database

31. Additional file 1: of Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples

32. The impact of parental role distributions, work participation, and stress factors on family health-related outcomes: Study protocol of the prospective multi-method cohort 'Dresden Study on Parenting, Work, and Mental Health' (DREAM)

33. Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry

34. Bedarfsorientierte, interdisziplinäre und sektorenübergreifende Versorgung von Methamphetamin-konsumierenden Müttern - eine qualitative Befragung der Akteure des 'Dresdner Versorgungspfades Crystal'

41. Corrigendum to 'Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie AGO Study Group'

45. Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients

48. The FNTB-609G > C polymorphism as a possible predictive factor for efficacy of lonafarnib-treatment? Exploratory analysis of a randomized phase II clinical trial in stage IIb-IV ovarian cancer, treated with first-line platinum-based chemotherapy with or without lonafarnib

49. Outcome parameters in node-negative vulvar cancer - subset analysis of the AGO CaRE-1 study

50. AGO Vulva CaRE-1 multicenter study - adjuvant radio(chemo)therapy in vulvar cancer

Catalog

Books, media, physical & digital resources